Arca
Skip to content
Tools
Tools

BCL11A: BCL11 transcription factor A

Transcription factor.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on BCL11A, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Other 1

Approved1

  • Exagamglogene autotemcel

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        Exagamglogene autotemcelApprovedVertex PharmaceuticalsGeneGene editing negative modulatorB-cell lymphoma/leukemia 11A gene editing negative modulator7

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 7 in all, from ClinicalTrials.gov.
        Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney DiseaseExagamglogene autotemcelPhase 1Not yet recruitingCajal Therapeutics Inc.Oct 28, 2026
        A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.Exagamglogene autotemcelEarly phase 1RecruitingCajal Therapeutics Inc.May 11, 2026
        An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)Exagamglogene autotemcelPhase 1 / Phase 2RecruitingComplement TherapeuticsFeb 6, 2026
        Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseaseExagamglogene autotemcelPhase 3RecruitingVertex Pharmaceuticals IncorporatedJul 28, 2022
        Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)Exagamglogene autotemcelPhase 3Active, not recruitingVertex Pharmaceuticals IncorporatedMay 2, 2022
        Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)Exagamglogene autotemcelPhase 3Active, not recruitingVertex Pharmaceuticals IncorporatedApr 15, 2022
        A Long-term Follow-up Study in Participants Who Received CTX001Exagamglogene autotemcelPhase 3Enrolling by invitationVertex Pharmaceuticals IncorporatedDec 23, 2019

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Dias-Logan syndrome0.78
        • Intellectual disability0.66
        • Benign prostatic hyperplasia0.51
        • Hereditary disease0.51
        • Cancer0.51
        • Intelligence0.49
        • Mathematical ability0.45
        • Neurodevelopmental delay0.44
        • Risk-taking behaviour0.43

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5498502, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9H165, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.